IBS News

Subscribe to IBS News feed
IBS Patient Community - IBSpatient.org - IBS News
Updated: 1 hour 51 min ago

Google-Ask the Doctors: Probiotics might lessen symptoms of depression - The Spokesman-Review

Sep 22, 2017
Ask the Doctors: Probiotics might lessen symptoms of depression The Spokesman-Review Researchers in Canada followed 44 adults with irritable bowel syndrome, or IBS, a bowel disorder. IBS causes abdominal pain and diarrhea or constipation, and there is evidence that probiotics can ease some of those symptoms. The subjects in this study ... View the full article

Google-7 natural laxatives to relieve constipation - Bel Marra Health

Sep 22, 2017
Bel Marra Health 7 natural laxatives to relieve constipation Bel Marra Health Common causes of constipation include low fiber intake, low water intake, having a food intolerance, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), side effects of medications, lack of physical activity, overuse of laxatives, and ... View the full article

Google-Yale Study Claims Individualized Diets For IBS May Be Better Than Placebo - Collective Evolution

Sep 22, 2017
Collective Evolution Yale Study Claims Individualized Diets For IBS May Be Better Than Placebo Collective Evolution Symptoms include abdominal pain and cramping, bloating and swelling of the stomach, flatulence, constipation and/or diarrhea, lethargy, and bladder problems. In a survey by IFFGD, 2,000 patients with IBS reported that diagnosis of their IBS was ... View the full article

Google-IBS support group to meet Sept. 26 - Watertown Public Opinion

Sep 22, 2017
IBS support group to meet Sept. 26 Watertown Public Opinion A support group for people with Irritable Bowel Syndrome (IBS) will meet on Tuesday, Sept. 26, at 6:30 p.m. in the ... The support group works to educate those who are living with IBS and to increase awareness of the disorder. Deidra VanGilder, who ... View the full article

Google-RedHill BioPharma: Highly De-Risked And Undervalued With A Deep Pipeline - Seeking Alpha

Sep 22, 2017
RedHill BioPharma: Highly De-Risked And Undervalued With A Deep Pipeline Seeking Alpha It primarily tests pre-existing drugs in new inflammatory indications, focusing primarily on gastrointestinal (GI) indications such as Irritable Bowel Syndrome with Diarrhea (IBS-D), Crohn's Disease (CD), and acute gastroenteritis/gastritis. RDHL does ... Redhill Biopharma Ltd. (NASDAQ:RDHL) Receives New Coverage from Analysts at UBS AGDispatch Tribunal all 6 news articles » View the full article

Google-Leaky gut: What is it, and what does it mean for you? - Harvard Health (blog)

Sep 22, 2017
Harvard Health (blog) Leaky gut: What is it, and what does it mean for you? Harvard Health (blog) We already know that increased intestinal permeability plays a role in certain gastrointestinal conditions such as celiac disease, Crohn's disease, and irritable bowel syndrome. The biggest question is whether or not a leaky gut may cause problems ... View the full article

Pubmed-Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population.

Sep 22, 2017
Related Articles Evaluation and performance of a newly developed patient-reported outcome instrument for diarrhea-predominant irritable bowel syndrome in a clinical study population. Therap Adv Gastroenterol. 2017 Sep;10(9):673-687 Authors: Delgado-Herrera L, Lasch K, Zeiher B, Lembo AJ, Drossman DA, Banderas B, Rosa K, Lademacher C, Arbuckle R Abstract BACKGROUND: To evaluate the psychometric properties of the newly developed seven-item Irritable Bowel Syndrome - Diarrhea predominant (IBS-D) Daily Symptom Diary and four-item Event Log using phase II clinical trial safety and efficacy data in patients with IBS-D. This instrument measures diarrhea (stool frequency and stool consistency), abdominal pain related to IBS-D (stomach pain, abdominal pain, abdominal cramps), immediate need to have a bowel movement (immediate need and accident occurrence), bloating, pressure, gas, and incomplete evacuation. METHODS: Psychometric properties and responsiveness of the instrument were evaluated in a clinical trial population [ClinicalTrials.gov identifier: NCT01494233]. RESULTS: A total of 434 patients were included in the analyses. Significant differences were found among severity groups (p < 0.01) defined by IBS Patient Global Impression of Severity (PGI-S) and IBS Patient Global Impression of Change (PGI-C). Severity scores for each Diary and Event Log item score and five-item, four-item, and three-item summary scores were calculated. Between-group differences in changes over time were significant for all summary scores in groups stratified by changes in PGI-S (p < 0.05), two of six Diary items, and three of four Event Log items; a one-grade change in PGI-S was considered a meaningful difference with mean change scores on all Diary items -0.13 to -0.86 [standard deviation (SD) 0.79-1.39]. Similarly, for patients who reported being 'slightly improved' (considered a clinically meaningful difference) on the PGI-C, mean change scores on Diary items ranged from -0.45 to -1.55 (SD 0.69-1.39). All estimates of clinically important change for each item and all summary scores were small and should be considered preliminary. These results are aligned with the previous standalone psychometric study regarding reliability and validity tests. CONCLUSIONS: These analyses provide evidence of the psychometric properties of the IBS-D Daily Symptom Diary and Event Log in a clinical trial population. PMID: 28932269 [PubMed] View the full article

Pubmed-Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial.

Sep 22, 2017
Related Articles Repeat treatment with rifaximin improves irritable bowel syndrome-related quality of life: a secondary analysis of a randomized, double-blind, placebo-controlled trial. Therap Adv Gastroenterol. 2017 Sep;10(9):689-699 Authors: Cash BD, Pimentel M, Rao SSC, Weinstock L, Chang L, Heimanson Z, Lembo A Abstract BACKGROUND: Diarrhea-predominant irritable bowel syndrome (IBS-D) impairs patient quality of life (QOL). Rifaximin is an oral, nonsystemic antibiotic indicated for IBS-D. The objective of this secondary analysis was to evaluate rifaximin retreatment on IBS-related QOL in patients with IBS-D. METHODS: Patients received open-label rifaximin 550 mg three times daily for 2 weeks. Clinical responders [simultaneously meeting weekly response criteria for abdominal pain (⩾30% improvement from baseline in mean weekly pain score) and stool consistency (⩾50% decrease from baseline in number of days/week with Bristol Stool Scale (BSS) type 6 or 7 stools) during ⩾2 of first 4 weeks posttreatment] who relapsed during an up to 18-week treatment-free observation phase were randomly assigned to receive two 2-week courses of double-blind rifaximin or placebo, separated by 10 weeks. A validated 34-item IBS-QOL questionnaire examined patient responses in 8 domains. RESULTS: The 2579 patients receiving open-label rifaximin experienced a mean improvement from baseline in IBS-QOL overall score of 54.9%. Responders to open-label rifaximin (n = 1074 of 2438 evaluable; 44.1%) had significantly greater improvement from baseline in IBS-QOL overall and all eight subdomain scores, including dysphoria, food avoidance, interference with activity, body image, and sexual function versus nonresponders at 4 weeks posttreatment (n = 1364; p < 0.001 for all comparisons). A significantly greater percentage of responders to open-label rifaximin achieved the minimally clinically important difference (MCID; ⩾14-point improvement from baseline) in the overall IBS-QOL score versus nonresponders [n = 561 (52.2%) versus n = 287 (21.0%); p < 0.0001]. Among 636 patients with IBS-D relapse, the MCID in the overall IBS-QOL score was achieved by a significantly greater percentage of patients receiving double-blind rifaximin versus placebo (38.6% versus 29.6%, respectively; p = 0.009). CONCLUSIONS: Open-label and blinded retreatment with a short course (2 weeks) of rifaximin improved IBS-QOL in patients with IBS-D [ClinicalTrials.gov identifier: NCT01543178]. PMID: 28932270 [PubMed] View the full article

Pubmed-The place of eluxadoline in the management of irritable bowel syndrome with diarrhea.

Sep 22, 2017
Related Articles The place of eluxadoline in the management of irritable bowel syndrome with diarrhea. Therap Adv Gastroenterol. 2017 Sep;10(9):715-725 Authors: Levio S, Cash BD Abstract Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by abdominal pain associated with defecation with altered stool frequency or stool form. The global prevalence of IBS ranges from 10% to 15% and total healthcare cost attributable to IBS is significant. Among individuals with IBS, the condition has dramatic effects on health-related quality of life, work and school productivity, and activities of daily living. It may be diagnosed with confidence, based on symptom-based diagnostic criteria, exclusion of alarm features and directed diagnostic testing. Management of IBS typically begins with dietary and lifestyle modifications, progressing to over-the-counter therapies, and then to prescription medications, both approved and nonapproved for IBS. This narrative summarizes the efficacy and safety of three US Food and Drug Administration (FDA)-approved prescription therapies for IBS with diarrhea (IBS-D), with a focus on the most recently marketed agent, eluxadoline, and its role in the treatment IBS-D. PMID: 28932272 [PubMed] View the full article

Pubmed-The global impact of IBS: time to think about IBS-specific models of care?

Sep 22, 2017
Related Articles The global impact of IBS: time to think about IBS-specific models of care? Therap Adv Gastroenterol. 2017 Sep;10(9):727-736 Authors: Corsetti M, Whorwell P Abstract Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal (GI) disorder that can significantly erode the quality of life (QoL) of sufferers and places a major cost burden on healthcare services. This paper reviews the literature on the impact of IBS on healthcare services and society, including a recent report on the subject, in order to formulate a plan for the future. A completely different model of care for these patients is recommended based on this review and the experience of the two authors who have been treating patients with functional GI disorders for 20 and 35 years, respectively. PMID: 28932273 [PubMed] View the full article

Pubmed-Brain responses to vestibular pain and its anticipation in women with Genito-Pelvic Pain/Penetration Disorder.

Sep 22, 2017
Related Articles Brain responses to vestibular pain and its anticipation in women with Genito-Pelvic Pain/Penetration Disorder. Neuroimage Clin. 2017;16:477-490 Authors: Pazmany E, Ly HG, Aerts L, Kano M, Bergeron S, Verhaeghe J, Peeters R, Tack J, Dupont P, Enzlin P, Van Oudenhove L Abstract OBJECTIVE: In DSM-5, pain-related fear during anticipation of vaginal penetration is a diagnostic criterion of Genito-Pelvic Pain/Penetration Disorder (GPPPD). We aimed to investigate subjective and brain responses during anticipatory fear and subsequent induction of vestibular pain in women with GPPPD. METHODS: Women with GPPPD (n = 18) and age-matched healthy controls (HC) (n = 15) underwent fMRI scanning during vestibular pain induction at individually titrated pain threshold after a cued anticipation period. (Pain-related) fear and anxiety traits were measured with questionnaires prior to scanning, and anticipatory fear and pain intensity were rated during scanning using visual analog scales. RESULTS: Women with GPPPD reported significantly higher levels of anticipatory fear and pain intensity. During anticipation and pain induction they had stronger and more extensive brain responses in regions involved in cognitive and affective aspects of pain perception, but the group difference did not reach significance for the anticipation condition. Pain-related fear and anxiety traits as well as anticipatory fear ratings were positively associated with pain ratings in GPPPD, but not in HC. Further, in HC, a negative association was found between anticipatory fear ratings and brain responses in regions involved in cognitive and affective aspects of pain perception, but not in women with GPPPD. CONCLUSIONS: Women with GPPPD are characterized by increased subjective and brain responses to vestibular pain and, to a lesser extent, its anticipation, with fear and anxiety associated with responses to pain, supporting the introduction of anticipatory fear as a criterion of GPPPD in DSM-5. PMID: 28932680 [PubMed - in process] View the full article

Google-Individualized diet may be the best medicine-free treatment for irritable bowel syndrome - Bel Marra Health

Sep 22, 2017
Bel Marra Health Individualized diet may be the best medicine-free treatment for irritable bowel syndrome Bel Marra Health individualized diet While a number of treatments exist for IBS, a new study out of Yale University has found that following an individualized diet based on food sensitivities is the best medicine-free approach to help reduce symptom onset. View the full article

Google-It might not be the gluten making you bloated - Good Food

Sep 21, 2017
It might not be the gluten making you bloated Good Food I've had irritable bowel syndrome (IBS) for as long as I can remember, and way back in 2003 decided it was worth cutting out gluten just to see what would happen. What followed was a miraculous discovery of the joys of regular bowel movements and a ... View the full article

Google-Continued Trouble Ahead For Ardelyx - Seeking Alpha

Sep 21, 2017
Continued Trouble Ahead For Ardelyx Seeking Alpha The trial is being dubbed, T3MPO-2, and the company's stock price declined 65% after their T3MPO-1 trial for irritable bowel syndrome with constipation (IBS-C) patients. ... In fact, the 26-week trial will probably produce worse numbers in terms of ... View the full article

Google-What causes irregular bowel movements? - Bel Marra Health

Sep 21, 2017
Bel Marra Health What causes irregular bowel movements? Bel Marra Health Irritable bowel syndrome: Also known as IBS or spastic colon, this bowel disorder includes abdominal pain and changes in bowel habits. It can cause either extreme diarrhea or constipation and is a chronic condition. Irritable bowel syndrome is the most ... View the full article

Google-Individualized diets for irritable bowel syndrome better than placebo - Science Daily

Sep 21, 2017
Medical Xpress Individualized diets for irritable bowel syndrome better than placebo Science Daily As many as one in five adults meet the criteria for irritable bowel syndrome (IBS), a disorder that can cause chronic abdominal pain, gas, diarrhea, and constipation. Many patients with IBS try diets based on blood tests that claim to identify foods ... Individualized IBS diets reduce symptoms better than placeboHealio all 3 news articles » View the full article

Google-Woman diagnosed with stage three bowel cancer at 23 after being convinced she had irritable bowel syndrome - Mirror.co.uk

Sep 21, 2017
Mirror.co.uk Woman diagnosed with stage three bowel cancer at 23 after being convinced she had irritable bowel syndrome Mirror.co.uk When she was a teenager Rachael said she had gone to the GP around five or six times due to problems, but after they tested her for Crohn's disease and colitis she was always told it was irritable bowel syndrome. Rachael added: "In the months leading ... View the full article

Google-This is Part of FMS, Too? - Fibromyalgia News Today

Sep 21, 2017
Fibromyalgia News Today This is Part of FMS, Too? Fibromyalgia News Today I have had IBS-C (irritable bowel syndrome, constipation-predominant) since I was a young child. Coming from a stressful home, I would sometimes go without a bowel movement for more than a week. The onset of cramps, spasms, and pain was intense, and ... View the full article

Google-How to Help Your Child Handle Chronic GI Problems at School - Health Essentials from Cleveland Clinic (blog)

Sep 21, 2017
How to Help Your Child Handle Chronic GI Problems at School Health Essentials from Cleveland Clinic (blog) Chronic abdominal pain is a set of conditions where, although clinical evaluation and work-up do not reveal a cause, children truly perceive pain. Conditions that fall into this category include irritable bowel syndrome, functional constipation ... View the full article

Google-Individualized diets for irritable bowel syndrome better than placebo - Medical Xpress

Sep 21, 2017
Individualized diets for irritable bowel syndrome better than placebo Medical Xpress As many as one in five adults meet the criteria for irritable bowel syndrome (IBS), a disorder that can cause chronic abdominal pain, gas, diarrhea, and constipation. Many patients with IBS try diets based on blood tests that claim to identify foods ... View the full article

Pages